Key result
POLARx cryoballoon matches Arctic Front Advance PRO with 100% PVI success but longer procedural times.
Why the study?
POLARx is a novel cryoballoon designed to improve outcomes, but clinical evidence evaluating its procedural safety and efficacy was restricted to a case report.
Does the novel POLARx cryoballoon improve procedural efficacy and safety compared to the historical AFAP cryoballoon in patients undergoing atrial fibrillation ablation?
Cohort
No
Does the novel POLARx cryoballoon improve procedural efficacy and safety compared to the historical AFAP cryoballoon in patients undergoing atrial fibrillation ablation?
The novel POLARx cryoballoon demonstrated similar procedural efficacy (100% pulmonary vein isolation) and safety compared to the established AFAP platform, though it was associated with longer procedural times.
Answers are grounded in this paper and cite their sources.
Similar PVI success and safety with POLARx versus AFAP in this cohort; hypothesis-generating and requires randomized confirmation before practice change.
INTRODUCTION: Catheter ablation is superior to drugs regarding atrial fibrillation (AF) recurrence, symptoms improvement, and mortality reduction in heart failure. POLARx™ is a novel cryoballoon, with technical improvements seeking to improve outcomes. So far, its clinical evidence is restricted to a case report. METHODS: To compare the POLARx™ cryoballoon procedural safety and efficacy to the already established Arctic Front Advance PRO™ (AFAP) in a single-center cohort study, consecutive patients undergoing AF cryoablation with the POLARx™ were enrolled. Data were prospectively gathered. POLARx™ patients were compared with a historical cohort of patients submitted to AF cryoablation with the AFAP. The primary end-point, all pulmonary veins isolation, was 100% in both groups. The complication rate was similar (0% POLARx™ vs. 5.7% AFAP, p = .39). The median total procedural time was longer in the POLARx™ group (90 min vs. 60 min, p < .001), but the overall time-to-isolation (TTI; 44.8 s vs. 39 s, p = .253) and ablation time (15 min vs. 13.7 min, p = .122) was similar between POLARx™ and AFAP groups, respectively. Despite equal TTI, the POLARx™ had a lower minimal temperature reached (-57°C vs -47°C, p < .001). CONCLUSION: The novel POLARx™ cryoballoon had similar efficacy and safety compared with the AFAP. It was also associated with longer procedural times, similar TTI, and lower minimum temperature reached.
No takes yet. Share an insight, caveat, or question.
Kochi et al. (2021) conducted a cohort in Atrial fibrillation. POLARx cryoballoon vs. Arctic Front Advance PRO (AFAP) cryoballoon was evaluated on All pulmonary veins isolation. The POLARx cryoballoon achieved 100% pulmonary vein isolation, identical to the Arctic Front Advance PRO, with similar complication rates but longer procedural times.
Synapse has enriched 10 related papers. Consider them for comparative context: